Huons Biopharma Ships First Botulinum Toxin Export to China

First Shipment Dispatched

Full-Scale Distribution in China Expected in the Second Half of the Year

Huons Biopharma, a subsidiary of Huons Global, is shipping the first batch of the botulinum toxin 'Hutox®' (marketed as Liztox in Korea) to target the Chinese market.

Huons Biopharma shipped the first export batch of botulinum toxin 'Hutox®' to China on the 16th. Huons Biopharma

On March 16, Huons Biopharma announced that it had signed a supply agreement for botulinum toxin with the wholly owned distribution subsidiary of its Chinese partner IMeik Technology and shipped the first volume.

Hutox is a botulinum toxin (Clostridium botulinum toxin type A)-based pharmaceutical used for both cosmetic and therapeutic purposes. It is mainly used for improving glabellar lines and crow’s feet wrinkles.

In 2022, IMeik acquired exclusive import and distribution rights for botulinum toxin products from Huons Biopharma in the China region, including Macau and Hong Kong. Following subsequent development in China, IMeik received product approval for Hutox 100 units from the National Medical Products Administration (NMPA) of China in January this year.

The Hutox shipped this time is expected to begin full-scale distribution in China as early as the second half of this year after passing quality inspections by local health authorities. As a result, Hutox will become the seventh botulinum toxin product to be commercialized in China, and only the second from a Korean company to achieve commercialization there.

A company representative stated, "Starting with this shipment, we will closely cooperate with IMeik to ensure smooth distribution and marketing in China," adding, "We expect Hutox to begin recording substantial global sales starting this year."

This content was produced with the assistance of AI translation services.